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Intermediary metabolismTransferrin receptor (Tfr1) is ubiquitously expressed, but its roles in non-hematopoietic cells are incompletely
understood. We used a tissue-speciﬁc conditional knockout strategy to ask whether skeletal muscle required
Tfr1 for iron uptake. We found that iron assimilation via Tfr1 was critical for skeletal muscle metabolism, and
that iron deﬁciency in muscle led to dramatic changes, not only in muscle, but also in adipose tissue and liver.
Inactivation of Tfr1 incapacitated normal energy production in muscle, leading to growth arrest and a muted
attempt to switch to fatty acid β oxidation, using up fat stores. Starvation signals stimulated gluconeogenesis in the
liver, but amino acid substrates became limiting and hypoglycemia ensued. Surprisingly, the liver was also iron deﬁ-
cient, and production of the iron regulatory hormone hepcidin was depressed. Our observations reveal a complex in-
teraction between iron homeostasis and metabolism that has implications for metabolic and iron disorders.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Iron, required by all mammalian cells, circulates bound to plasma
transferrin (Tf). Cells express transferrin receptor (Tfr1), which can
bind Fe-Tf and internalize it by receptor-mediated endocytosis
(Hentze et al., 2004). Vesicles bearing Fe-Tf/Tfr1 fuse with endosomes,
where low pH releases iron from Tf for transmembrane transfer to the
cytoplasm. Iron is then stored, used directly, or incorporated into
heme or Fe–S clusters for utilization in globin proteins, cytochromes,
oxidative phosphorylation complexes and other enzymes. Apo-Tf and
Tfr1 recycle to the cell surface for further rounds of iron uptake.
Although Tfr1 is widely expressed, it is not universally required for
iron assimilation. Through genetic manipulations in mice, we showed
that most early embryonic tissues develop normally in the absence of
Tfr1, and most adult tissues can form from Tfr1−/− embryonic stem
cells (Levy et al., 1999; Ned et al., 2003). Furthermore, most tissues
are not iron deﬁcient in mice with a congenital deﬁciency of Tf, but
rather accumulate excess iron (Trenor et al., 2000). However, hemato-
poietic cells, particularly erythroid precursors, have a critical require-
ment for Tfr1 (Levy et al., 1999; Ned et al., 2003) and Tf (Trenor et al.,
2000). We hypothesized that non-hematopoietic cells might use7710, USA.
ws).
. This is an open access article underalternative iron uptake mechanisms, and such mechanisms have been
described (Sturrock et al., 1990; Barisani et al., 1995; Baker et al.,
1998; Yang et al., 2002; Oudit et al., 2003; Liuzzi et al., 2006; Li et al.,
2009).We considered that skeletal muscle is a major site of iron utiliza-
tion (Andrews, 1999), and asked whether Tfr1 was important.
We found that skeletal muscle has a critical requirement for Tfr1.
Mice in which the muscle Tfr1 gene has been inactivated during
embryogenesis appeared normal at birth, but rapidly developed a
dramatic and lethal phenotype. They stopped growing, lost adipose
tissue, developed hepatic steatosis and experienced profound hypogly-
cemia before death. Although Tfr1 was intact in hepatocytes, the liver
also became iron deﬁcient early in the development of the phenotype
and decreased production of the iron regulatory hormone hepcidin.
The abnormal phenotypewas corrected by administration of parenteral
iron to saturate transferrin, increasing non-Tf-bound iron, indicating
that neonatal muscle iron deﬁciency was responsible for the severe,
systemic metabolic derangement.
2. Materials and Methods
2.1. Animal Experiments
We crossed 129/SvEv mice bearing a ﬂoxed Tfr1 (gene symbol Tfrc)
allele (Chen et al., 2015) with B6.Cg-Tg (ACTA1-cre)79Jme/J micethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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control of the human skeletal muscle actin promoter (Miniou et al.,
1999). We backcrossed with 129/SvEv mice for more than 10 genera-
tions. As indicated in the ﬁgure legends, microarray experiments and
experiments shown in Fig. 1A,C,F,G,H,I, and Fig S1C used mice with
similar, mixed 129/C57BL6 backgrounds and experiments shown in all
other ﬁgures used mice with a homogeneous 129/SvEv background.
Apart from several days' difference in length of survival, the pheno-
types were very similar on both backgrounds. Animals were geno-
typed by PCR using genomic DNA from toe clips (Truett et al.,
2000). Primers are described in Table S1. Blood glucose was mea-
sured at P6 using the FreeStyle Freedom Lite monitoring system (Ab-
bott). Insulin levels were measured using a Rat/Mouse Insulin ELISA
kit (EMD Millipore) according to the manufacturer's protocol. Total
ketones were measured using a Total Ketone Bodies kit (Wako Diag-
nostics) according to the manufacturer's protocol. Glycogen mea-
surements were performed as previously described (Thyfault et al.,
2007). Non-heme iron was measured as previously described (Levy
et al., 1999). For iron rescue experiments, mice were injected IP
with 5 mg of Uniferon® 100 (25 μL) at P3, or at both P3 and P21.
All procedures were carried out under protocols approved by the
Duke Animal Care and Use Committee. Sample sizes included in an-
imal protocols were determined with assistance from the Duke Bio-
statistics Core.2.2. RNA Extraction, Microarray Analysis and Quantitative PCR
RNA was extracted using an RNA isolation kit (Qiagen) according
to themanufacturer's instructions. Samples were treated with DNase
I (Qiagen) to remove genomic DNA. Microarray analysis was per-
formed using Affymetrix Mouse Expression Array 430A 2.0. RNA
quality control, hybridization and data analysis were performed by
the Duke University Microarray Shared Resource (see Supplemental
Experimental Procedures) and results have been deposited in the
NCBI Gene Expression Omnibus database, accession number
GSE68675. For quantitative PCR, cDNA from liver and skeletal muscle
was synthesized using the iScript cDNA synthesis kit (Bio-Rad) ac-
cording to the manufacturer's instructions. Real time quantiﬁcation
was performed using iQ SYBR Green Super mix (Bio-Rad). The prim-
er sequences are described in Table S1.2.3. Immunoblots
Protein lysates were prepared from muscle and liver using RIPA
buffer (50 nM NaCl, 20 mM Tris, pH 7.5, 1 mM EDTA,1% NP40,
0.1% SDS, 0.5% Na deoxycholate), protease inhibitors and phospha-
tase inhibitors (Roche Applied Science). Quantiﬁcation was per-
formed using Bio-Rad Dc Protein Assay (Bio-Rad). Lysates we
subjected to electrophoresis on TGX™ precast gels (Bio-Rad) and
transferred to Immune-Blot® PVDF membrane (Bio-Rad). Mem-
branes were incubated with primary and secondary antibodies listed
in Table S2, developed with chemiluminescence ECL Western blot-
ting detection solutions (GE Healthcare) and exposed to autoradiog-
raphy ﬁlm (HiBlot CL®, Denville Scientiﬁc). Signal intensity was
quantiﬁed using Image J software.2.4. Morphometric analysis
Tibialis anterior (TA) muscle was isolated from mice and imme-
diately ﬂash frozen in embedding media. Muscle cross-sections
were stained with Alexa Fluor® 594 WGA (Life Technologies,
Invitrogen) and individual ﬁbers were counted using Image J
software.2.5. Oil Red O Staining
Liver was harvested from mice and frozen in embedding media.
10 μm sections were stained with Oil Red O as previously reported
(Carson and Hladlik, 2009).
2.6. IRP-IRE Binding Assay
IRP-IRE binding assays were carried out using the LightShift™
Chemiluminescent RNA EMSA according to manufacturer's instructions
(Pierce Biotechnologies). The IRE sequence is shown in Table S1.
2.7. Enzymatic Assays
Aconitase activity was measured in isolated mitochondria using
the Aconitase Enzyme Activity Microplate Assay Kit (Abcam) according
to themanufacturer's instructions.Mitochondriawere isolated as previ-
ously described (Wieckowski et al., 2009). Complex II activity wasmea-
sured in gastrocnemius tissue lysates as previously reported (Spinazzi
et al., 2011).
2.8. Metabolomics Analyses
Amino acids, acylcarnitines and organic acids were analyzed using
stable isotope dilution techniques. Amino acids and acylcarnitine
measurementsweremade by ﬂow injection tandemmass spectrometry
as described previously (An et al., 2004;Wu et al., 2004). The data were
acquired using a Waters Acquity™ UPLC system equipped with a triple
quadrupole detector and a data system controlled by MassLynx 4.1
operating system (Waters). Organic acids were quantiﬁed using
methods described previously (Jensen et al., 2006) employing Trace
Ultra GC coupled to ISQMS operating under Xcalibur 2.2 (Thermo Fisher
Scientiﬁc).
2.9. Proteomics Analyses
Proteomics analysis on 6 gastrocnemius samples was carried out by
the Duke Proteomics and Metabolomics Shared Resource (see Supple-
mental Experimental Procedures). Proteomics results have been depos-
ited in the MassIVE database (https://massive.ucsd.edu/ProteoSAFe/
static/massive.jsp), ID MSV000079328.
2.10. Statistical Analyses
Unpaired Student's T testswere performedusingMicrosoft ®Excel®
2011 software. P values less than 0.05were considered signiﬁcant. Rep-
resentation of the p values are as follows: not signiﬁcant (ns), p N 0.05,
*p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
3. Results
3.1. Tfr1 Deﬁciency in Skeletal Muscle Causes early Postnatal Death
We selectively inactivated the murine Tfr1 gene using a skeletal
muscle actin (HSA)-Cre transgene, expressed from embryonic day 9
and highly speciﬁc for skeletal muscle (Miniou et al., 1999), to recom-
bine loxP sites ﬂanking Tfr1 exons 3 to 6 (Chen et al., 2015) to generate
Tfr1mu/mu mice. Tfr1mu/mu mice were born in Mendelian ratios. We
conﬁrmed that they expressed little Tfr1 mRNA or protein in skeletal
muscle (Fig S1). They were slightly smaller than Tfr1ﬂ/ﬂ wild type
(WT) littermates at birth, fell behind in growth (Fig. 1A,B) and typically
died or had to be euthanized before P13 on a mixed background or P11
on a homogeneous 129/SvEv background. Because the males usually
lived longer and therefore had larger tissues, we continued our analysis
with male mice unless otherwise noted. Necropsy revealed that
the Tfr1mu/mu mice had small muscles (Fig. 1C,D) but the total number
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changes such as central nuclei or misalignment of Z-lines but we saw
lipid droplets in diaphragmatic muscle by electron microscopy (not
shown).
We found striking changes in other tissues, even though Tfr1
was targeted only in muscle. Fat pads were present early in life in
Tfr1mu/mu mice (not shown) but disappeared by the time animals
showed distress (Fig. 1F). Before growth delay was apparent the ab-
dominal organs appeared grossly normal (not shown), but later the
Tfr1mu/mu liver contained excess neutral lipid and both liver and
spleen were small compared to controls (Fig. 1G–I). Although nor-
mal at day 4 (not shown), serum glucose became low as the pheno-
type developed (Fig. 1J). At P6 serum insulin ranged from 0.5 to
6.7 ng/mL in control animals (n = 18) but was undetectable in
almost all mutants (n= 17). Twomutant animals that did havemea-
surable serum insulin (1.3 and 1.5 ng/mL) also had normal serum
glucose (117 and 94 mg/dL respectively), suggesting that they had
not yet developed the full phenotype. Low serum glucose, coupled
with non-detectable serum insulin, would exacerbate the glucose
deﬁcit in insulin-responsive tissues –muscle and fat – likely contrib-
uting to the phenotype. Serum ketones were elevated at P6 in both
control and mutant animals, consistent with their young age, but
markedly more elevated in the mutants (Fig. 1K). Surprisingly,
liver glycogen was indistinguishable between controls and mutants,
but muscle glycogen was decreased in Tfr1mu/mu mice (Fig. S1D).
The animals may have succumbed to hypoglycemia, but attempts
to rescue the animals by administering intraperitoneal glucose did
not substantially prolong survival (not shown). Alternatively, they
may have died from respiratory failure due to diaphragmatic insuf-
ﬁciency. We speculate that normal placental function spared the
mice before birth, when serum glucose levels are maintained by
the mother (Wang et al., 1995) and that changes developed when
the animals no longer beneﬁted from the placenta's capacity to
correct metabolic abnormalities and substrates for gluconeogenesis
decreased, as described later.3.2. Muscle Iron Deﬁciency and Impaired Oxidative Phosphorylation
We asked whether skeletal muscle was iron deﬁcient in the absence
of Tfr1. Inmicewith homogeneous 129backgrounds and earlier onset of
the phenotype, the total amount of muscle iron, per gram of tissue, was
similar between Tfr1mu/mu mice and controls at P6 as measured by
inductively coupled plasma mass spectrometry (not shown). However,
muscle ferritin was decreased (Fig. 2A,B) and iron regulatory protein
binding activity was increased in Tfr1mu/mu animals at P6 (Fig. 2C,D),
indicative of iron deﬁciency. Myoglobin was decreased, consistent
with insufﬁciency of its co-factor heme (Fig S2A,B). This suggests that
the animals had a normal endowment of iron at birth, but additional
ironwasnot assimilated formuscle growth and functional iron deﬁcien-
cy ensued.
Heme and Fe–S clusters are critical cofactors for electron transport
chain (ETC) complexes and failure of mitochondrial respiration might
contribute to the phenotype observed in Tfr1mu/mu mice. We evaluated
the integrity of ETC complexes I to V at P6 by immunoblotting with a
cocktail of antibodies that detects labile protein components of each.
Although complex V was represented similarly in WT and Tfr1mu/mu
mice, the mutants were deﬁcient in the other complexes (Fig. 2E,F),
which require iron (Xu et al., 2013). We conﬁrmed complex II deﬁcien-
cy by enzymatic assay (Fig. 2G) and also observed that a key Fe–S con-
taining protein of complex I, Ndufs3, was markedly decreased (Fig.
2H,I). The deﬁciencies in ETC complexes did not appear to result from
a substantial decrease in the number of mitochondria because complex
V levels (Fig. 2E) were similar inWT and Tfr1mu/mumice and expression
of mitochondria-encoded mRNA transcripts (Fig S2C) was not substan-
tially different between WT and Tfr1mu/mu mice. These results supportthe interpretation that Tfr1mu/mu muscle was iron deﬁcient, leading to
impaired mitochondrial respiration.
3.3. Tfr1mu/mu Mice are Rescued by Iron
We hypothesized that if Tfr1 is needed for iron assimilation by
skeletal muscle, it might be possible to rescue the mutant phenotype
by causing iron overload. We knew that muscle could take up non-
Tf-bound iron in animals with a congenital deﬁciency of Tf (Trenor
et al., 2000). We treated WT and Tfr1mu/mu mice with a large dose
of iron dextran at P3 to increase circulating non-Tf-bound iron.
With this treatment, Tfr1mu/mu mice appeared healthy, had normal
body weights (Fig. 3A,B), survived for at least 4 weeks with no
further intervention, and survived for substantially longer with a
second treatment. Both WT and Tfr1mu/mu mice had marked tissue
iron overload as expected, and the extent of iron loading was similar
(Fig. 3C,D; note log scale). H-ferritin was similarly increased in mice
of both genotypes (Fig. 3E,F). At 4 weeks Tfr1mu/mu mice had normal
serum glucose levels (Fig. 3G). We conclude that iron deﬁciency is
the root cause of the mutant phenotype, and that it can be rescued
by administration of excess iron.
3.4. Decreased Liver Iron in Tfr1mu/mu Mice
Hepatic steatosis and hypoglycemia indicated that muscle iron
deﬁciency led to changes in the liver, even though the Tfr1 gene
was intact and expressed (Fig. 4A). While we observed substantial
variability, likely due to variation in the onset of the abnormal phe-
notype, liver non-heme iron was unexpectedly decreased at P6,
and H-ferritin was reduced, indicating liver iron deﬁciency (Fig.
4B–D). Consistent with hepatic iron deﬁciency, activity of the
Fe–S cluster-dependent enzyme mitochondrial aconitase was de-
creased (Fig. 4E) and mRNA encoding the iron regulatory hor-
mone hepcidin was markedly diminished (Fig. 4F). Decreased
liver iron did not appear to be due to systemic iron deﬁciency be-
cause hemoglobin and hematocrits were not signiﬁcantly differ-
ent between P6 mutant and control mice (not shown). These
results suggest that loss of Tfr1 in skeletal muscle led to hepatic
iron deﬁciency.
3.5. Gene Expression Changes in Tfr1mu/mu Muscle and Liver
We proﬁled mRNA expression changes in Tfr1mu/mu tissues rel-
ative to WT controls [results deposited online (Barrientos and
Andrews, 2015)]. In this experiment we used mice on a mixed
background because they lived longer and therefore had larger tis-
sues for mRNA extraction. We analyzed muscle and liver from
mice at P5 (early), before the phenotype was grossly apparent,
and P9 (late), when the phenotype had developed and the animals
were within several days of death. We used Gene Set Enrichment
Analysis [GSEA; (Subramanian et al., 2005; Mootha et al., 2003)]
to look for informative patterns. Few genes were differentially reg-
ulated in Tfr1mu/mu muscle early, but Tfr1 mRNA containing non-
deleted exons was upregulated, consistent with iron deﬁciency.
Other upregulated genes included Cacna2d1, a subunit of a
voltage-dependent calcium channel that has been implicated in
non-Tf-bound iron uptake in the heart, (Oudit et al., 2003),
angiopoietin-like 4 (Angptl4), carbonic anhydrase 2 (Car2) and ret-
inol saturase (Retsat). The most strongly downregulated genes in
early muscle included frizzled b (Frzb), low density lipoprotein
receptor-related 2 binding protein (Lrp2bp), H-ras-like suppressor
(Hrasls), growth factor receptor-bound protein 14 (Grb14),
contactin associated protein-like 2 (Cntnap2) and myosin heavy
chain 4 (Myh4).
Later, after the phenotype became apparent, more genes were
differentially regulated in mutant muscle. Upregulated genes were
1708 T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717annotated by GSEA as associated with hypoxia,1 Mapk signaling,2
glycolysis3, Ppar signaling,4 fatty acid metabolism5 and Tnfα
signaling.6 Predicted targets of Nfat7 and estrogen receptor-related
protein α (Esrra, also called Nr3b1)8 were particularly prominent.
The most strongly upregulated gene was ankyrin repeat domain 2
(Ankrd2), which has been reported to inhibit myoblast differentia-
tion (Mohamed et al., 2013). Angptl4 and brain-derived neurotrophic
factor (Bdnf), both induced by fasting (Kersten et al., 2009; Walsh
et al., 2015), were also upregulated. Genes downregulated in late
muscle were annotated as being involved in metabolism of amino
acids, heme metabolism9 and mTorc1 signaling.10
We also examined hepatic gene expression. We saw many changes
early, before steatosis was apparent. The most prominent categories of
upregulated genes were those involved in Tnfα signaling via NF-κB,11
apoptosis12, hypoxia13, lipid and lipoprotein metabolism,14 insulin
signaling,15 PPAR signaling16 and fatty acid, triacylglycerol and ke-
tone metabolism.17 The most strongly upregulated were regulator of
G-protein 16 (Rgs16), leptin receptor (Lepr), oxidative stress growth
inhibitor 1 (Osgin1), D site albumin promoter binding protein (Dbp)
and pantothenate kinase 1 (Pank1). Genes downregulated in early
liver included, strikingly, more than 50 genes, mostly E2F targets,
which are involved in DNA replication and the cell cycle. The most
strongly downregulated gene was Hamp, encoding the iron regulatory
hormone hepcidin, consistent with Fig. 4F.
After the phenotype became apparent, at the late time point, more
genes were differentially regulated in the mutant liver. Upregulated
genes were annotated in GSEA as involved in TNFα signaling, metabo-
lism of lipids and lipoproteins, insulin signaling, adipocytokine signal-
ing, carbohydrate metabolism and lipid, fatty acid, triacylglycerol
and ketone body metabolism. Rgs16, Lepr and Pank1 were again
among the most highly induced, alongwith G protein-coupled receptor
64 (Gpr64), cytochrome P450 family 2, subfamily c, polypeptide 39
(Cyp2c39), apolipoprotein A-IV (Apoa4) and thioredoxin interacting
protein (Txnip). Transcripts encoding enzymes involved in gluconeo-
genesis – Ldhb, encoding a subunit of lactate dehydrogenase, Pck1,
encoding phosphoenolpyruvate carboxykinase, and G6pc, encoding
glucose-6-phosphatase –were markedly increased, as were hepatocyte
nuclear factor 4 alpha (Hnf4a) and nuclear receptor subfamily 4, group
A, member 1 (Nr4a1), both transcription factors that induce gluconeo-
genesis. Of note, Hnf4a has been reported to repress hepcidin expres-
sion (Courselaud et al., 2002). Genes downregulated in the mutant
liver at the later time included many E2F target genes involved in the
cell cycle, transmembrane transporters, and genes involved in heme
metabolism. The most strongly downregulated genes were Slc22a7,
Slc22a29, both organic anion transporters. Other members of the Slc22
family of organic anion transporters were also downregulated.1 Bnip3, Cdkn1a, Irs2,Maff, Nﬁl3, Klf6, Fos, Pnrc1, Foxo3, Pim1, Angptl4, Ctgf,Mxi1, Errﬁ1
2 Fos, Nr4a1, Hspa1a, Hspa1b, Bdnf
3 Irs2, Angptl4, Fbp2, Egln3
4 Angptl4, Ctgf, Anrd1, Pdpk1, Acsl1, Slc27a1, Fabp3
5 Ca2, Acsl1, Retsat, Hadhb, Etfdh, Acss1, Eci2
6 Cdkn1a, Irs2,Maff, Nﬁl3, Klf6, Fos, Pnrc1, Nr4a1, Nfkbi1, Gadd45b, Klf10
7 Bdnf, Nr4a1, Fos, Ctgf, Csrp3, Cdkn1a, Pdk4, Acss1, Irs2
8 Bdnf, Csrp3, Cdkn1a, Pnrc1, Insr, Errﬁ1, Tnfrsf12a, Abtb2, Gna13, Arhgap24, Asxl1, Golga4,
Fabp3, Pim1, Hspb7, Nﬁl3, Etfdh, Tln1, Bnip3, Ca2, Fam69b
9 E2f2, Pc, Alas2, Fam46c, Spta1, Snca, Slc25a37
10 Sqle, Ctsc, Igfbp5, Tmem97, Ldlr,Me1, Slc37a4, Glrx, Psat1, Serp1
11 Per1, Klf10, Bmp2, Nfkbia, Eif1, Jun., Nr4a1, Maff, Ppap2b, Sgk1, Irs2, Cebpb, Zfp36,
Gadd45b, Zbtb10, Nr4a2, Btg2, Nfe2l2, Klf9, Tiparp, Clcf1
12 Jun., Bmp2, Btg2, Gadd45b, Retsat, App, Txnip, Tnfrsf12a, Erbb3, Bcl2l11, H1f0, Gstm1
13 Jun., Irs2,Maff, Zfp36, Tiparp, Angptl4, Pck1, Errﬁ1, Egfr, Nedd4l, Upg2, Slc37a4
14 Ppap2b, Angptl4, Trib3, Lpin2, Acox1, Abcc3, Lpin1, Chka, Chkb, Cpt1a, Cyp7b1, Me1,
Nr1d1, Lss, Pnpla2
15 Irs2, Pck1, G6pc, Eif4ebp1, Cblb, Cblc, Insr, Gys2
16 Angptl4, Pck1, Acox1, Cpt1a,Me1, Nr1d1
17 Angptl4, Trib3, Chka, Lss, Atf53.6. Metabolic Changes
To better understand the complex phenotype of Tfr1mu/mu mice, we
considered molecular events that might cause arrested growth, hepatic
steatosis and hypoglycemia. We examined skeletal muscle after the
phenotype was grossly apparent and observed increased expression of
BdnfmRNA (microarray data) and increased phosphorylation of AMPK
(Fig S3A), consistent with an attempt to stimulate fatty acid oxidation
and glucose uptake. We also observed decreased phosphorylation of
AKT, consistent with a decrease in muscle growth, and, accordingly,
decreased phosphorylation of proteins downstream of the AKT target
mTOR (Fig S3B–D). The ratio of Map1lc3-II (LC3-II) to LC3-I was in-
creased, suggesting inductionof autophagy (Fig S3E). All of these chang-
es represent responses to energy insufﬁciency or nutrient deprivation.
To evaluate metabolic changes, we carried out a metabolomics anal-
ysis on muscle, liver and serum fromWT and Tfr1mu/mu mice at P4 and
P6 on a 129 background, before and after the phenotype was apparent,
respectively (Fig. 5). All results are shown because there were qualita-
tive and quantitative differences between the two time points, but for
simplicity the P6 results, from after the phenotype had developed, will
be discussed primarily.
In Tfr1mu/mu muscle we observed increased accumulation of three
tricarboxylic acid (TCA) cycle intermediates – citrate, α-ketoglutarate,
and succinate, as well as succinyl-carnitine (C4-DC), which derives
from succinyl-CoA – and decreased amounts of fumarate and malate.
These changes may be attributable to decreased activity of aconitase
and succinate dehydrogenase enzymes, which both require Fe–S cluster
co-factors. We also saw progressive elevation of C4OH (3-OH butyryl
carnitine) suggesting increasing ketone delivery to or ketolysis within
the mutant muscle. Odd chain acylcarnitines (C5OH, C5:1, C3DC)
were increased, consistent with increased amino acid catabolism and
diminished amino acids detected in muscle. Increased branched chain
amino acids (leucine, isoleucine) probably contributed to the increase
in C5OH. Some β oxidation intermediates were slightly increased, but
interestingly not to levels typically observed during starvation or exer-
cise. Tfr1mu/mu muscle showed diminished anaplerotic amino acids,
consistent with increased amino acid catabolism in an attempt to fuel
the TCA cycle. Aspartic acid, one of the anaplerotic amino acids, is also
used for several transamination reactions. Importantly, there were de-
creased levels of lactate and alanine, both precursors for gluconeogene-
sis that are typically shuttled frommuscle to liver during starvation and
exercise.
We observed increased muscle citrate, usually a signal of plenty,
which can inhibit phosphofructokinase and glycolysis and may inhibit
β oxidation indirectly. At the same time, impaired oxidative phosphor-
ylationmay lead to an increased AMP/ATP ratio and activation of AMPK
(Fig S3A), which is a signal of energy insufﬁciency. In addition to these
mixed signals, we observed increased acetylcarnitine (C2), which
derives from acetyl CoA and might reﬂect mitochondrial accumulation
of this crucial metabolite.
The livers of Tfr1mu/mu mice should stabilize serum glucose through
gluconeogenesis but themice became hypoglycemic towards the end of
theﬁrstweek of life. A previous report linked hepatocyte iron deﬁciency
to decreased gluconeogenesis in an in vitro system (Klempa et al., 1989)
but in our animals changes in the metabolomics proﬁle suggested that
amino acid insufﬁciency was the reason for failure of gluconeogenesis.
Amounts of almost all amino acids were severely decreased in serum
at P6. Hepatic citratewasmarkedly elevated, in spite ofmetabolic stress,
possibly because diminished liver iron caused decreased mitochondrial
aconitase activity (Fig. 4E). In contrast to muscle, where beta-oxidation
may have been impaired due to ETC deﬁciencies, there was a strong
signature for hepatic fatty acid catabolism, with markedly elevated
even chain acylcarnitines.
Serum from Tfr1mu/mu mice was also more severely affected at P6
than P4. The older mice had increased C4OH suggesting increased
ketone delivery or ketolysis in tissues such as muscle and heart. There
Fig. 1. Phenotypic characterization of Tfr1mu/mu mice. (A) Appearance ofWT and Tfr1mu/mu mice at P9 (C57/129mixed background). (B) Bodyweights at P1 (WT n= 7, Tfr1mu/mu n= 7;
129 background), and P6 (WT n = 5, Tfr1mu/mu n = 10; 129 background). (C) Tibialis anterior (TA) and gastrocnemius (GA) muscles from P9WT and Tfr1mu/mu mice (C57/129 mixed
background). (D) Ratio of tibialis anterior (TA) mass to tibia length at P6 (WT n = 25, Tfr1mu/mu n = 27; 129 background). (E) Tibialis anterior ﬁber numbers in Tfr1mu/mu and WT
mice at P6 (WT n = 5, Tfr1mu/mu n = 4; 129 background). (F) P9 Tfr1mu/mu mice lacked body fat pads found in control mice, as indicated with arrows (C57/129 mixed background).
(G) Grossmorphology of P9WT and Tfr1mu/mu livers (WT n=3, Tfr1mu/mu n=3; C57/129mixed background). (H) Oil RedO staining (red) of liver sections (C57/129mixed background).
(I) Grossmorphology of spleens at P9 (C57/129mixed background). (J) Serum glucosemeasurements at P6 (malemice;WT n=5, Tfr1mu/mu n=10; 129 background). (K) Serum ketone
measurements at P6 (male mice; WT n = 12, Tfr1mu/mu n = 12; 129 background). For all panels with graphs: Error bars represent standard deviation, ** p ≤ 0.01, **** p ≤ 0.0001.
1709T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717was a robust increase in several long chain acylcarnitines derived from
long chain acyl-CoA intermediates of β oxidation. As noted earlier, all
amino acids were strongly diminished, likely contributing to the failure
of gluconeogenesis.
3.7. Proteomic Analysis
To further evaluate the phenotype, we subjected muscle proteins
from P6 (late) WT and Tfr1mu/mu mice to mass spectrometry-basedproteomic analysis. We assessed relative protein expression levels and
lysine acetylation modiﬁcations (data online at https://massive.ucsd.
edu/ProteoSAFe/static/massive.jsp, ID MSV000079328). The relative
expression levels of most proteins were not different between WT and
mutant muscle samples. However, consistent with mRNA proﬁling re-
sults, the amounts of myosin heavy chain 4 (Myh4) and eukaryotic
translation elongation factor 1 alpha 2 (Eef1a2) were strongly dimin-
ished and the amount of acetyl-coA acyltransferase 2 (Acaa2) was
increased (Fig. 6A). The most striking changes were in proteins that
1710 T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717did not show alteredmRNA expression: components of ETC complexes I
(Ndufa5, 6, 9, 10; Ndufb9; Ndufs1, 3, 4, 5, 7, and Ndufv1), II (Sdha,
Sdhb), and cytochrome C were all depleted in mutant mice compared
to WT animals (Fig. 6A). Each of these complexes and many of these
proteins use Fe–S clusters or heme as co-factors. Others have reported
decreased expression of ETC proteins in iron deﬁcient muscle
(Rensvold et al., 2013) and noted that mRNA and protein levels did
not always correlate. Decreased ETC proteins may reﬂect instability of
their complexes when iron is insufﬁcient.Fig. 2. Skeletal muscles with deletion of Tfr1 have decreased iron levels. (A,B) H-ferritin (Fth)
loading control; WT n = 5, Tfr1mu/mu n = 4; 129 background]. (C,D) Iron regulatory protein (
compared to WT (WT n = 5, Tfr1mu/mu n = 4; 129 background). (E,F) Levels of representat
from P6 Tfr1mu/mu mice compared to WT. The amount of ATP5A, a protein component of com
(WT n = 6, Tfr1mu/mu n = 6; 129 background). (G) Enzymatic activity of Complex II in P6 Tfr
S containing proteinNdufs3 in P6muscle fromTfr1mu/mumice [ribosomeprotein L19 (Rpl19) loa
standard deviation; * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.We examined the acetyl-proteome of P6 Tfr1mu/mu muscle by isolat-
ing lysine-acetylated peptides using an anti-acetyl lysine antibody
followed by mass spectrometry analysis (Fig. 6B, Table S3). Strikingly,
nearly all proteins with increased acetylation in the mutant were mito-
chondrial. Multiple subunits of complex V, which do not contain iron
and were not diminished in total protein levels, were hyperacetylated.
Furthermore, nearly every enzyme of the TCA cycle was multiply
hyperacetylated. The only exception was succinate dehydrogenase, an
iron-containing enzyme shared with oxidative phosphorylation. Aslevels in P6 Tfr1mu/mu muscle compared to WT littermates [ribosome protein L19 (Rpl19)
IRP) binding to a biotinylated iron regulatory element (IRE) probe in P6 Tfr1mu/mu muscle
ive proteins for complexes I (Ndufb8), II (Sdhb), III (Uqcrc2), and IV (Mtco1) in muscle
plex V, appeared unchanged and was used in panel F to normalize for relative intensity
1mu/mu muscle compared to WT (WT n = 5, Tfr1mu/mu n = 3; 129 background). (H,I) Fe–
ding control;WTn=5, Tfr1mu/mu n=4; 129 background]. All panels: error bars represent
Fig. 3. Exogenous iron rescues the Tfr1mu/mu phenotype. (A) Representative adult Tfr1mu/mu and WT mice treated with iron dextran. (B) Body weights of untreated WT and iron dextran
treatedWT and Tfr1mu/mumice.+ Fe indicates iron treatment (untreatedWTn=4, treatedWTn=4, treated Tfr1mu/mu n=3). (C)Non-heme liver iron inWTand Tfr1mu/mumice treated
with iron.+ Fe indicatesmice treatedwith iron (note Log10 scale; untreatedWT n=4, treatedWT n=4, treated Tfr1mu/mu n=3). (D) Non-heme skeletalmuscle iron inWT and Tfr1mu/
mumice treatedwith iron.+Fe indicatesmice treatedwith iron (note Log10 scale; untreatedWTn=4, treatedWTn=4, treated Tfr1mu/mu n=3). (E,F)Muscle H-ferritin (Fth) inWT and
Tfr1mu/mu mice treated with iron. + Fe indicates mice treated with iron [ribosome protein L19 (Rpl19) loading control; untreatedWT n= 4, treatedWT n= 4, treated Tfr1mu/mu n= 3].
(G) Blood glucose levels in WT and Tfr1mu/mu mice treated with iron. + Fe indicates mice treated with iron (untreated WT n = 4, treated WT n = 4, treated Tfr1mu/mu n = 3).
Differences in blood glucose were not signiﬁcant. For all panels: mice are one-month old females on a 129 background. Error bars represent standard deviation; ns = no signif-
icant, ** p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
1711T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717mentioned earlier, amounts of Sdha and Sdhb were diminished, likely
resulting in decreased activity of that enzyme.
Mitochondrial aconitase, Aco2, was the most highly
hyperacetylated protein in Tfr1mu/mu muscle (Table S3). While it
was hyperacetylated on multiple residues, acetylation on K245 was
markedly increased relative to control muscle. K245would be buried
within the protein and inaccessible in its native conformation (Dick
Brennan, Duke Biochemistry, personal communication). Further-
more, acetylation of K245, if it occurred before protein folding,would disrupt the normal conformation. As mentioned earlier,
Aco2 contains an Fe–S cluster, which may be limiting in iron-
deﬁcient cells. We speculate that, similar to what has been shown
with Aco1 (Walden et al., 2006), unavailability of the Fe–S cluster
may result in a dramatic conformational change in Aco2, making
K245 accessible for acetylation. This would be consistent with the
increase in muscle citrate we observed (Fig. 5).
Acetylation of TCA cycle enzymes has been reported (Anderson and
Hirschey, 2012) but its consequences are not well understood. If
Fig. 4.Hepatic iron is decreased in Tfr1mu/mumice. (A) Relative Tfr1mRNA levels in livers from P6WT and Tfr1mu/mumice (WT n=10, Tfr1mu/mu n=11; 129 background). (B) Non-heme
liver iron in P6WTand Tfr1mu/mumice (WTn=8, Tfr1mu/mu n=8, 129 background). (C,D) LiverH-ferritin (Fth) inWT and Tfr1mu/mumice [ribosome protein L19 (Rpl19) loading control;
WT n= 8 and Tfr1mu/mu n = 9; 129 background]. (E) Aconitase activity in liver from P6WT and Tfr1mu/mu mice (WT n= 10, Tfr1mu/mu n = 12; 129 background). (F) Relative hepcidin
mRNA levels in liver from P6WT and Tfr1mu/mu mice (WT n= 10, Tfr1mu/mu n= 11; 129 background). Error bars represent standard deviation; ns= no signiﬁcant, * p ≤ 0.05, ** p ≤ 0.01,
***p ≤ 0.001.
1712 T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717acetylation activates the enzymes, it might represent an attempt to in-
crease the activity of the TCA cycle. However, in the absence of a
functional ETC, this would be ineffective. Furthermore, it appears
that the pyruvate dehydrogenase complex may be inactive, causing
a switch away from the TCA cycle by inhibiting conversion of pyru-
vate to acetyl CoA. We observed increased acetylation of K321 of py-
ruvate dehydrogenase alpha 1 (Pdha1) (Table S3), which decreases
its activity (Ozden et al., 2014), and increased phosphorylation of
S293 (Fig S3F), which has the same effect (Rardin et al., 2009). The
phosphorylation of S293 may be carried out by pyruvate dehydroge-
nase kinase isoenzyme 4 (Pdk4) and Pdk4 mRNA was markedly in-
creased in our microarray proﬁles.
Interestingly, many enzymes important for β oxidation were
also hyperacetylated (Fig. 6B, Table S3). Acetylation of these pro-
teins has been described in normal heart (Foster et al., 2013) and
other cell types (Kim et al., 2006) but for the most part the func-
tional consequences have not been determined. Lysine acetylation
of long chain acyl-CoA dehydrogenase (Acadl) on two speciﬁcresidues was shown to inhibit activity (Bharathi et al., 2013), but
neither of those residues was hyperacetylated in our mutant muscle
samples.
Increased mitochondrial acetyl CoA might drive enzymatic or non-
enzymatic acetylation of mitochondrial proteins. Furthermore, de-
creased NAD levels, predicted due to impairment of complex I activity,
could contribute to hyperacetylation by inhibiting sirtuin deacetylase
activity. We noted that many of the acetylation events we observed
corresponded to previously described targets of sirtuin 3 (Sirt3), amito-
chondrial deacetylase (Rardin et al., 2013). Althoughwedid not attempt
to measure Sirt3 activity directly, it is likely impaired, contributing to
the metabolic defects. We compared our results to results from
Sirt3−/− muscle proteomic analysis (CR Kahn, B Gibson, M Rardin
personal communication of unpublished results) and found that, of a
total of 349 hyperacetylated peptides in Tfr1mu/mu muscle and
397 hyperacetylated peptides in Sirt3−/−muscle, there were 70 pep-
tides common to both datasets that changed in the same direction
(Table S4).
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We found that Tfr1 is important in murine skeletal muscle, and that
iron deﬁciency consequent to the loss of Tfr1 set off a chain of events
that resulted in systemic metabolic abnormalities and early postnatal
lethality. Tfr1mu/mu mice appeared normal at birth and had normalFig. 5.Metabolic changes in Tfr1mu/mu mice. (Left panel) Heat map ofmetabolomics results from
(males; 129 background). Blue— decreased, red— increased, white— not signiﬁcantly different
VLC— very long chain, AC— acylcarnitine. Because the animals were small, we pooled tissue fro
Tfr1mu/mu (total 23mice of each genotype). At P6we analyzed6 pools each forWT and Tfr1mu/mu
Tfr1mu/mu mice were compared to P6WT mice. (Right panels) Diagrammatic representation of
highlighted in blue are decreased and metabolites highlighted in red are increased.numbers of skeletal muscle ﬁbers, making it unlikely that they suffered
a developmental defect. Furthermore, there was no evidence of muscle
atrophy or necrosis. However, over the ﬁrst week of life the mutant
animals stopped growing, lost body fat, developed hepatic steatosis
and became incapable of maintaining normal serum glucose levels,
with death ensuing before the end of the second week. This dramaticgastrocnemius muscle, liver and serum from P4 (4d) and P6 (6d)WT and Tfr1mu/mu mice
fromWT, gray— not determined; SC— short chain,MC—medium chain, LC— long chain,
m 3 to 4mice for each sample in this analysis. At P4 we analyzed 6 pools each forWT and
(total 18mice of each genotype). P4 Tfr1mu/mumicewere compared to P4WTmice and P6
pathways changing in the muscle (top) and liver (bottom) of Tfr1mu/mu mice. Metabolites
Fig. 6. Proteomic analysis shows increased acetylation in proteins in muscle of Tfr1mu/mu mice. (A) Heat map showing the global protein expression of three pools of Tfr1mu/mu gastroc-
nemius (9–10 mice per pool) and three pools of WT gastrocnemius (7 mice per pool) at P6 (males; 129 background). The table lists proteins with signiﬁcant changes in expression in
Tfr1mu/mu mice compared to WT mice. (B) Heat map of acetyl proteome of three Tfr1mu/mu and three WT mice at 6 days of age. We used the same pooled samples as in (A). The table
lists proteins with signiﬁcant increase in acetylation in Tfr1mu/mu mice compared to WT mice.
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dextran, showing that muscle iron deﬁciency was the root cause.
Ineffective iron assimilation, due to loss of Tfr1, disrupted muscle
metabolism. Representative proteins from iron-containing ETC com-
plexes I to IV were decreased and enzymatic assay conﬁrmed that com-
plex II activity was impaired in skeletal muscle when the phenotype
was apparent. Complex V subunits and TCA cycle enzymes were
hyperacetylated. While the consequences of hyperacetylation areuncertain for most of these enzymes, in one case we can infer a func-
tional outcome. Aco2, the mitochondrial aconitase involved in the TCA
cycle, was highly acetylated on a lysine residue that is not normally ex-
posed. Its accessibility indicates that Aco2 was acetylated when it was
not properly folded, likely because of unavailability of Fe–S clusters
due to iron deﬁciency, consistent with the decreased Aco2 activity and
accumulation of citrate in muscle. Increased Pdk4 expression and spe-
ciﬁc acetylation and phosphorylation events affecting Pdha1 likely
1715T. Barrientos et al. / EBioMedicine 2 (2015) 1705–1717inhibited the pyruvate dehydrogenase complex in skeletal muscle, pre-
cluding conversion of pyruvate to acetyl CoA. This may have caused a
switch to attempted use of β-oxidation of fatty acids and/or ketones in
muscle. However, we can only infer the metabolic consequences, be-
cause we have not done comprehensive metabolic ﬂux experiments,
which would be very difﬁcult in newborn mice.
Metabolic changes were not limited to skeletal muscle, although
Tfr1 was only deﬁcient in that tissue. Body fat pads disappeared, sug-
gesting that lipolysis ensued, presumably to provide a source of energy
for muscle, and the liver became steatotic. Tfr1-null muscle showed
increased expression of Angptl4 mRNA, suggesting a starvation-like
response. Starvation should promote lipolysis for increased fatty acid
delivery to the muscle, but failure of the ETC would preclude effective
β oxidation. We do not know why the levels of acylcarnitines were
lower in muscle than liver, but this might suggest a defect in muscle
fatty acid uptake or in the activity of carnitine palmitoyltransferase 1
(Cpt1). The presence of lipid droplets in the diaphragm was consistent
with increased fatty acid delivery and decreased β oxidation. Angptl4
expression has also been associated with hypoglycemia, inhibition of
gluconeogenesis and hepatic steatosis (Xu et al., 2005), as observed in
our mice.
There was evidence that the liver was attempting to respond by in-
creasing gluconeogenesis to provide glucose for muscle metabolism.
Several mRNAs that encode proteins inducing gluconeogenesis were
increased in the liver, including Rgs16 (Pashkov et al., 2011), Pank1
(Leonardi et al., 2010) and Txnip (Muoio, 2007). Lactate dehydrogenase
b (Ldhb) was markedly induced, suggesting that the liver was trying to
use lactate to produce pyruvate through the Cori cycle. Transcripts
encoding phosphoenolpyruvate carboxykinase (Pck1) and the catalytic
subunit of glucose-6-phosphatase (G6pc) were also increased. We
note that expression of Pck1 and G6pc is controlled by Rev.-erbα
(Nr1d1), a transcription factor that binds heme, and heme binding is
reported to repress Pck1 and G6pc expression (Yin et al., 2007). We
speculate that decreased availability of heme, either from iron deﬁcien-
cy in skeletal muscle or liver, de-repressed expression of these
gluconeogenic enzymes. However, in spite of their increased expres-
sion, Tfr1-null mice developed progressive hypoglycemia, indicating
that gluconeogenesis failed. This is likely attributable to lack of sub-
strate, as amino acids were profoundly decreased in muscle, serum
and liver.
Even before steatosis developed, the liver showed profound down-
regulation of a large number of genes with various roles in the cell
cycle, most of which are annotated as E2f targets. We are not certain
whywe see this striking pattern, butwe note that Txnip, which is highly
expressed in mutant muscle and liver, has been shown to cause cell
cycle arrest (Han et al., 2003).
Severe iron deﬁciency in skeletalmuscle compromises production of
Fe–S clusters important for ETC complexes and other enzymes. Howev-
er, our Tfr1-null muscle differed frommuscle fromhuman patients with
Fe–S cluster depletion due to deﬁciency of the Fe–S cluster scaffold
protein ISCU (Crooks et al., 2014). Similar to our mice, those patients
had decreased mitochondrial aconitase activity, as expected. There
were some similarities in gene expression but they were modest, and
muscle mRNA expression of several key genes, including TST, ALAS1
and SLC25A28 was increased in the human patients, while expression
of those genes or close homologs (Tst, Alas2, Slc25a37) was strongly de-
creased in muscle in our mice. Crooks et al. observed that ﬁbroblast
growth factor 21 (FGF21) mRNAwasmarkedly induced in muscle sam-
ples from affected patients, but Fgf21 was not induced in muscle from
our mice (not shown). Furthermore, the patients were not reported to
have hepatic steatosis or hypoglycemia. These differences suggest that
loss of Tfr1 in skeletal muscle has consequences beyond depletion of
Fe–S clusters and the proteins that require them.
The pattern of increased lysine acetylation we observed by proteo-
mic analysis of Tfr1-null skeletal muscle was striking in two ways.
First, nearly all hyperacetylated proteins were mitochondrial and mosthypoacetylated proteins were not. Second, there was strong concor-
dance between acetylation events we observed and those observed in
Sirt3−/− muscle. Both observations suggest that Sirt3 may be less
active in Tfr1-null muscle, though we cannot exclude the possibility
that increasedmitochondrial acetyl CoA resulting from decreasedmito-
chondrial aconitase activity, or increased acetylase activity, contributed
to this pattern. It is possible that mitochondrial dysfunction has led to a
deﬁcit in acetyl donors outside of the mitochondria.
Surprisingly, iron deﬁciency in skeletal muscle also led to iron deﬁ-
ciency in the liver before the systemic phenotype was apparent. This
seems counterintuitive – onemight expect that a decrease in the ability
of themuscle to extract iron from circulating Tf might lead to increased
hepatic iron stores, but thatwas notwhatwe observed. There are sever-
al possible explanations. First, muscle iron deﬁciency might instigate an
as yet unidentiﬁed signal to the liver to decrease expression of the iron
regulatory hormone hepcidin andmobilize hepatic iron stores. A similar
signal has been described from the erythroid bone marrow to regulate
intestinal iron absorption (Finch, 1994), apparently by decreasing
hepcidin expression (Hentze et al., 2004). It was recently reported
that erythroferrone (Fam132b)might be a component of this “erythroid
regulator” (Kautz et al., 2014). Expression of erythroferrone was not
increased in Tfr1mu/mu muscle (not shown), even though this protein
has also been identiﬁed as myonectin and described as linking muscle
activity to adipose tissue and liver lipid metabolism (Seldin et al.,
2012). Alternatively, metabolic changes associated with iron deﬁciency
in Tfr1mu/mu muscle might alter hepatic iron homeostasis in a manner
not yet described. Regardless of the mechanism, decreased expression
of the iron regulatory hormone hepcidin should result in increased
iron availability to skeletal muscle. However, our results indicate that
this is futile when Tfr1 is inactive in muscle.
Our experiments have allowed us to examine the local and systemic
sequelae of severe, isolatedmuscle iron deﬁciency.While impairment of
iron-dependent enzymes in muscle might have been predicted, the
systemic effects are profound and surprising, and elucidate a previously
unappreciated link between iron homeostasis and intermediarymetab-
olism. We have studied an extreme situation, contrived by targeted
disruption of Tfr1, but we speculate that less severe muscle iron deﬁ-
ciency may have hitherto unappreciated effects on systemic energy
homeostasis. This could be quite signiﬁcant clinically, as iron deﬁciency
affects at least 15% of theworld's population and is the thirdmost prev-
alent cause of years lived with disability (Vos et al., 2012).
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